Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03255369 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2018-05-03
Summary
The recent increase in the number of cases of congenital microcephaly observed in Brazil is a reason of great concern. This increase occurred a few months after Zika virus (ZIKV) was introduced in the country, which was associated with reports of pregnant women presenting fever and rash illness during pregnancy. Thus, the hypothesis of a relationship between ZIKV infection and microcephaly became plausible. However, studies on the pathophysiology of maternal ZIKV infection, its consequences for the fetus, and the development of severe encephalopathy are still needed. Knowledge about the natural history of vertical transmission and its association with changes in fetal development in early life is still scarce. Studies on factors which determine the severity and clinical evolution, such as inflammatory response mechanisms, viral evolution, and development of serological tests to identify ZIKV infection, are still needed. The Aedes aegypti is responsible for the transmission of various types of viruses of interest to human health. Currently, it is primarily responsible for the transmission of the dengue, chikungunya, and ZIKV in epidemic proportions. In addition, it is not yet known whether there is an interaction between these viruses and whether the interaction can determine the severity of the disease. The aim of this study is to evaluate the natural history of ZIKV disease in two cohorts( pregnant women and children) starting with pregnant women or newborns or evennursing mothers, identifying risk biomarkers, mapping the anti-viral inflammatory response, evaluating the molecular evolution of the virus,which areimportant to determine the mechanisms of vertical viral infection and verify children neurodevelopment from birth to the end of 3rd year of life.
Conditions
- ZIKA VIRUS INFECTION
- Child Development
- Microcephaly
Interventions
- OTHER
-
Child exposed Zika virus proved
There will be applied Bayley Teste 3rd edition
Sponsors & Collaborators
-
Conselho Nacional de Desenvolvimento Científico e Tecnológico
collaborator OTHER_GOV -
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
collaborator OTHER_GOV -
Oswaldo Cruz Foundation
lead OTHER
Principal Investigators
-
Maria E Moreira, MD · Fundação Oswaldo Cruz
Eligibility
- Min Age
- 2 Days
- Max Age
- 3 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-02
- Primary Completion
- 2018-12-30
- Completion
- 2019-12-30
Countries
- Brazil
Study Locations
More Related Trials
-
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
NCT07347002 ·Status: ENROLLING_BY_INVITATION
-
Chikungunya Virus Vaccine Trial in Healthy Adults
NCT01489358 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
NCT06334393 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
NCT02531698 ·Status: COMPLETED ·Phase: PHASE2
-
Neurologic Manifestations of the Arbovirus Infection in Colombia
NCT03206541 ·Status: COMPLETED
-
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
NCT02367664 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
NCT03014089 ·Status: COMPLETED ·Phase: PHASE1
-
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
NCT05868733 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984 ·Status: RECRUITING ·Phase: PHASE3
-
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
NCT03879603 ·Status: COMPLETED ·Phase: PHASE1
-
Maternal Immunization With MenAfriVac™
NCT03746665 ·Status: UNKNOWN ·Phase: PHASE3
-
A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
NCT01303211 ·Status: WITHDRAWN
-
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
NCT02534935 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine to Prevent West Nile Virus Disease
NCT00106769 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
NCT00667602 ·Status: COMPLETED ·Phase: PHASE3
-
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
NCT06674837 ·Status: NOT_YET_RECRUITING
-
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
NCT01187433 ·Status: COMPLETED ·Phase: PHASE2
-
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil
NCT05403307 ·Status: COMPLETED
-
Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage
NCT01119482 ·Status: COMPLETED ·Phase: PHASE4
-
Conjugate Vaccine Against Meningococcus C a Brazilian Project
NCT02858570 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
NCT01352793 ·Status: COMPLETED ·Phase: PHASE3
-
Correlation Between Cytokines and the Severity of Meningococcal Disease
NCT01133834 ·Status: COMPLETED
-
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
NCT02990182 ·Status: UNKNOWN
-
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age
NCT02919293 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects
NCT00661557 ·Status: COMPLETED ·Phase: PHASE2